BR0307707A - nucleic acid encoding a g-protein coupled receptor and using it - Google Patents

nucleic acid encoding a g-protein coupled receptor and using it

Info

Publication number
BR0307707A
BR0307707A BR0307707-1A BR0307707A BR0307707A BR 0307707 A BR0307707 A BR 0307707A BR 0307707 A BR0307707 A BR 0307707A BR 0307707 A BR0307707 A BR 0307707A
Authority
BR
Brazil
Prior art keywords
nucleic acid
protein coupled
coupled receptor
acid encoding
receptor
Prior art date
Application number
BR0307707-1A
Other languages
Portuguese (pt)
Inventor
Haifeng Eishingdrelo
Holly Dressler
Cai Jidong
Paul Wright
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0219574.1A external-priority patent/GB0219574D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BR0307707A publication Critical patent/BR0307707A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

"áCIDO NUCLéICO CODIFICA O UM RECEPTOR ACOPLADO A PROTEìNA-G E USO DO MESMO". A presente invenção refere-se a um novo e útil receptor acoplado a proteína-G que está envolvido em transdução de sinal com relação a inflamação e resposta imunológica fisiológica. Também refere-se a métodos de uso de receptor para seleção de moléculas que podem modular a atividade do receptor. Tais moléculas facilmente podem ter aplicações em tratamento de uma pletora de doenças e distúrbios relacionados imunologicamente e inflamação."NUCLEIC ACID CODES A RECEIVER COUPLED TO G-PROTEIN AND USE". The present invention relates to a novel and useful G-protein coupled receptor that is involved in signal transduction with respect to inflammation and physiological immune response. It also refers to methods of receptor use for selecting molecules that can modulate receptor activity. Such molecules can readily have applications in treating a plethora of immunologically related diseases and disorders and inflammation.

BR0307707-1A 2002-02-14 2003-02-13 nucleic acid encoding a g-protein coupled receptor and using it BR0307707A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35668602P 2002-02-14 2002-02-14
GBGB0219574.1A GB0219574D0 (en) 2002-02-14 2002-08-22 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
PCT/US2003/004350 WO2003068803A2 (en) 2002-02-14 2003-02-13 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof

Publications (1)

Publication Number Publication Date
BR0307707A true BR0307707A (en) 2005-03-01

Family

ID=27736226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307707-1A BR0307707A (en) 2002-02-14 2003-02-13 nucleic acid encoding a g-protein coupled receptor and using it

Country Status (10)

Country Link
EP (1) EP1476460A4 (en)
JP (1) JP2005517398A (en)
CN (1) CN1642971A (en)
AU (1) AU2003213051A1 (en)
BR (1) BR0307707A (en)
CA (1) CA2476239A1 (en)
MX (1) MXPA04007006A (en)
NO (1) NO20043582L (en)
RU (1) RU2004127439A (en)
WO (1) WO2003068803A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003371A (en) 2007-09-28 2010-05-05 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof.
KR101137019B1 (en) * 2009-05-25 2012-05-24 한국생명공학연구원 A novel g protein coupled receptor and a use thereof
CN113588940B (en) * 2021-07-30 2023-05-12 菲鹏生物股份有限公司 Method and kit for improving sensitivity of indirect labeling

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1237909A2 (en) * 1999-11-16 2002-09-11 PHARMACIA & UPJOHN COMPANY Human g protein-coupled receptors
WO2001096567A1 (en) * 2000-06-15 2001-12-20 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof

Also Published As

Publication number Publication date
NO20043582L (en) 2004-08-27
WO2003068803A2 (en) 2003-08-21
WO2003068803A3 (en) 2004-07-29
JP2005517398A (en) 2005-06-16
CA2476239A1 (en) 2003-08-21
MXPA04007006A (en) 2004-10-11
RU2004127439A (en) 2005-04-10
AU2003213051A1 (en) 2003-09-04
EP1476460A4 (en) 2005-12-07
EP1476460A2 (en) 2004-11-17
CN1642971A (en) 2005-07-20

Similar Documents

Publication Publication Date Title
NO963280L (en) Use of anti-TNF antibodies as drugs in the treatment of diseases involving elevated interleukin-6 serum levels
ATE389724T1 (en) HUMAN DNASE I HYPERACTIVE VARIANTS
HUP0203567A2 (en) April receptor (bcma) and uses thereof
DE69433666D1 (en) FLAMMABILITY PROTEINS MAK-MIP-3, MIP-4 AND MIP-1Gamma
TR199902562T2 (en) De�i�tirilmi� TNF alfa molek�lleri
ATE361316T1 (en) CRYSTAL STRUCTURE OF A DEACETYLASE AND ITS INHIBITORS
DE60234453D1 (en) SUBSTITUTED PIPERAZINE AND DIAZEPANDERIVATES FOR USE AS HISTAMINE H3 RECEPTOR MODULATORS
DE69435268D1 (en) HUMAN METABOTROPIC RECEPTORS, THESE CODING NUCLEIC ACID AND ITS USE
ATE188969T1 (en) PEPTIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEINASES
AU1679395A (en) Mammalian monocyte chemoattractant protein receptors
PT101297A (en) GLITARY MITOGENIC FACTORS, THEIR PREPARATION AND UTILIZATION
BR0308339A (en) Indazoles Replaced with Anticancer Activity
TR199900318T2 (en) IL-8 receptor antagonists.
BR0307707A (en) nucleic acid encoding a g-protein coupled receptor and using it
Sun CITED2 mechanoregulation of matrix metalloproteinases
NO972313D0 (en) Peptides capable of binding to the GAP protein SH3 region, nucleotide sequences encoding this, and their production and use
BR9205967A (en) Interleukin receptor-labeled molecules treatment of inflammatory arthritis
BR0307122A (en) nucleic acid encoding a protein-coupled receptor and its uses
ATE317391T1 (en) 4-AMINOTETRAHYDROBENZISOXAZOLES OR -ISOTHIAZOLES
BR0214118A (en) nucleic acid encoding a protein-coupled receptor and uses thereof
PT1141305E (en) CHIMERIC GENE FORMED BY DNA SEQUENCES THAT CODIFIES THE ANTIGENIC DETERMINANTS OF FOUR PROTEINS BY L. INFANTUM
WO2004039334A3 (en) CALCIUM-SENSING RECEPTOR 2 (CaR2) AND METHODS FOR USING
BR9812531A (en) Combination of components, pharmaceutical preparation, production thereof, and use of the combination or pharmaceutical preparation
BR9807437A (en) CD23 anti-human gamma-1 and gamma-3 monoclonal antibodies and their use as therapeutics
BR0313307A (en) Mcp-1 receptor antagonists and method for their use

Legal Events

Date Code Title Description
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired